PRESS RELEASE January 4, 2018

Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Englewood Cliffs, NJ- January 4,2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare investment forums at the Hilton San Francisco […]

Keep Reading

December 14, 2017

Immune Pharmaceuticals Announces Change in Certifying Accountant

Englewood Cliffs, NJ, USA – December 14, 2017 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Audit Committee of the Company notified BDO USA, LLP (“BDO”) the Company’s independent registered public accounting firm for the […]

Keep Reading

December 13, 2017

Immune Pharmaceuticals Announces 2017 Annual Shareholder Meeting

Englewood Cliffs, NJ, USA – December 13, 2017 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Company filed a preliminary proxy statement with the United States Securities and Exchange Commission (“SEC”) on December 8, 2017 […]

Keep Reading

PRESS RELEASE December 11, 2017

Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

Englewood Cliffs, NJ, USA – December 11, 2017 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will have oversight […]

Keep Reading

December 11, 2017

Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

Englewood Cliffs, NJ, USA – December 11, 2017 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will […]

Keep Reading

November 27, 2017

Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer

Englewood Cliffs, New Jersey, USA – November 27, 2017 – Immune Pharmaceuticals Inc. (the “Company”) announced today the public disclosure of certain information regarding its continued listing on NASDAQ US and the departure of its VP Finance. Notice of Compliance with NASDAQ US Listing Rule On August 23, 2017, the Company received a letter from […]

Keep Reading

November 17, 2017

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

Englewood Cliffs, NJ – November 15, 2017 – Immune Pharmaceuticals Inc. (Nasdaq First North: IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update. Third Quarter 2017 and Recent Highlights On October […]

Keep Reading

PRESS RELEASE November 15, 2017

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

Englewood Cliffs, NJ – November 15, 2017 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update. Third Quarter 2017 and Recent Highlights On October 23, we […]

Keep Reading

PRESS RELEASE October 23, 2017

Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants

October 23, 2017 12:09 PM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (“Immune”) (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions […]

Keep Reading